Skip to content
Search

Latest Stories

NICE approves new combination drug for advanced breast cancer

The National Institute for Health and Care Excellence (NICE) has approved another potentially life-extending drug combination for advanced breast cancer patients.

Palbociclib (Ibrance) by Pfizer with fulvestrant will now be available through Cancer Drugs Fund (CDF) to women with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative or metastatic breast cancer.


Taken once-daily in pill form, palbociclib is a combination of two other NICE-approved drugs ribociclib and abemaciclib.

According to clinical trial evidence, palbociclib with fulvestrant increases the length of time before the disease progresses, in comparison to fulvestrant alone.

However, only the final trial results could confirm whether palbociclib could increase the length of time patients would live.

Meindert Boysen, director of the NICE Centre for Health Technology Evaluation, said: “The committee heard that treatments that can delay the need for chemotherapy, improve quality of life and extend how long people live in better health are important and would be welcomed. Palbociclib provides people with an alternative where NICE has already recommended two other drugs.”

NICE expects the new treatment to benefit up to 3,300 women who have already had endocrine treatment.

Blake Dark, NHS Commercial Medicines Director, said: “This targeted treatment has the potential to make a real difference to the quality of life for people with breast cancer, not only extending survival, but significantly delaying the need for chemotherapy."

“The NHS worked closely with the manufacturer of the treatment, Pfizer, to reach an agreement meaning that it will be available to patients immediately while further evidence is to be collected,” Dark added.

The drug combination is already available to NHS patients in England following NICE’s draft guidance recommendation in November.

More For You

Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less
Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less